@article{15ba55ae6fb843d08f0aafddcae180dd,
title = "IMbrave 050: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation",
abstract = "Hepatocellular carcinoma recurs in 70-80% of cases following potentially curative resection or ablation and the immune component of the liver microenvironment plays a key role in recurrence. Many immunosuppressive mechanisms implicated in HCC recurrence are modulated by VEGF and/or immune checkpoints such as PD-L1. Atezolizumab (PD-L1 inhibitor) plus bevacizumab (VEGF inhibitor) has been shown to significantly improve overall survival, progression-free survival and overall response rate in unresectable HCC. Dual PD-L1/VEGF blockade may be effective in reducing HCC recurrence by creating a more immune-favorable microenvironment. We describe the rationale and design of IMbrave 050 (NCT04102098), a randomized, open-label, Phase III study comparing atezolizumab plus bevacizumab versus active surveillance in HCC patients at high-risk of recurrence following curative resection or ablation. The primary end point is recurrence-free survival. Clinical Trial Registration: NCT0410209.",
keywords = "Ablation, Adjuvant treatment, Atezolizumab, Bevacizumab, Hepatocellular carcinoma, PD-L1, Recurrence-free survival, Resection, VEGF",
author = "Hack, {Stephen P.} and Jessica Spahn and Minshan Chen and Cheng, {Ann Lii} and Ahmed Kaseb and Masatoshi Kudo and Lee, {Han Chu} and Adam Yopp and Pierce Chow and Shukui Qin",
note = "Funding Information: SP Hack is a full-time employee of Roche/Genentech and holds Roche stock. J Spahn is a full-time employee of Roche/Genentech and holds Roche stock. A-L Cheng has received honoraria from AstraZeneca, Bayer Yakuhin, Eisai, Genentech/Roche and Lilly and consulting/advisory fees from AstraZeneca, Bayer Schering Pharma, BeiGene, Bristol-Myers Squibb, CSR Pharma Group, Eisai, Genentech/Roche, MSD, Novartis and Ono Pharmaceutical. M Kudo is a consultant of Bayer, Eisai, Ono, MSD, BMS, Eli Lilly and received research grant from Ono, BMS, MSD, Eisai, and received honoraria from Bayer, Eisai and BMS. HC Lee has received grants from Bayer, Bristol-Myers Squibb, Roche, MSD, AstraZeneca and Sillajen. P Chow has received honoraria and has participated in advisory boards for Sirtex Medical, Ipsen, BMS, Oncosil, Bayer, Roche, New B Innovation, MSD and BTG PLC. P Chow has received research funding support from Sirtex Medical, Ipsen, IQVIA, New B Innovation, MSD, Perspectum Diagnostic and Genentech. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Funding Information: Here, we describe the design of IMbrave 050, a Phase III, randomized, multicenter, open-label study of atezolizumab plus bevacizumab versus active surveillance in patients at high risk of disease recurrence following curative resection or ablation. The study is funded by F. Hoffmann-La Roche Ltd. Publisher Copyright: {\textcopyright} 2020 Stephen P. Hack.",
year = "2020",
month = may,
doi = "10.2217/fon-2020-0162",
language = "English (US)",
volume = "16",
pages = "975--989",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "15",
}